Xellia lands record profit of DKK 440 million (USD 64.5 million) - revenue increases by 15 percent.

Novo Nordisk-owned antibiotics producer Xellia Pharmaceuticals has publicized a strong year-end report with a record-high profit. However, the company still expects a difficult 2020.

Carl-Åke Carlsson, CEO of Xellia Pharmaceuticals. Photo: Xellia Pharmaceuticals / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles